Glucagon derivatives with improved stability

A peptide comprising the amino acid sequence of the following General Formula 1:

• (General Formula 1)
• X1-X2-QGTF-X7-SDYS-X12-X13-X14-X15-X16-X17-X18-
• X19-X20-X21-F-X23-X24-W-L-X27-X28-T
• wherein, in General Formula 1,
• X1 is desamino-histidine, N-dimethyl-histidine, β-hydroxyimidazopropionic acid, 4-imidazoacetic acid, β-carboxyimidazopropionic acid, tryptophan, tyrosine, or deleted;
• X2 is α-methyl-glutamic acid, aminoisobutyric acid (Aib), D-alanine, glycine, Sar(N-methylglycine), serine, or D-serine;
• X7 is threonine or valine;
• X12 is lysine or cysteine;
• X13 is tyrosine or cysteine;
• X14 is leucine or cysteine;
• X15 is aspartic acid, glutamic acid, or cysteine;
• X16 is glutamic acid, aspartic acid, serine, α-methyl-glutamic acid, or cysteine;
• X17 is aspartic acid, glutamic acid, lysine, arginine, serine, valine, or cysteine;
• X18 is aspartic acid, glutamic acid, arginine, or cysteine;
• X19 is alanine or cysteine;
• X20 is lysine, glutamic acid, glutamine, aspartic acid, or cysteine;
• X21 is aspartic acid, glutamic acid, valine, or cysteine;
• X23 is valine or arginine;
• X24 is valine, leucine, or glutamine;
• X27 is isoleucine or methionine;
• and
• X28 is arginine,
• with the proviso that the amino acid sequence of General Formula 1 excludes SEQ ID NO:
• 1 and SEQ ID NO:
• 12.